Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy.
Fiche publication
Date publication
mars 2023
Journal
Frontiers in nephrology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno
Tous les auteurs :
Jacquot L, Pointeau O, Roger-Villeboeuf C, Passilly-Degrace P, Belkaid R, Regazzoni I, Leemput J, Buch C, Demizieux L, Vergès B, Degrace P, Crater G, Jourdan T
Lien Pubmed
Résumé
This study assessed the efficacy of INV-202, a novel peripherally restricted cannabinoid type-1 receptor (CB1R) inverse agonist, in a streptozotocin-induced type-1 diabetes nephropathy mouse model.
Mots clés
CB1 receptors, diabetes, fibrosis, inverse agonism, nephropathy, peripherally-restricted
Référence
Front Nephrol. 2023 03 28;3:1138416